QR-koodi

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Abstract Patients with estrogen receptor (ER)‐positive breast cancer are less likely to achieve a pathological complete response (pCR) with neoadjuvant chemotherapy. Neoadjuvant endocrine therapy may be more appropriate than neoadjuvant chemotherapy in these hormone‐sensitive patients. Most patients...

Täydet tiedot

Tallennettuna:
Päätekijät: Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Wiley 2018-07-01
Sarja:Cancer Medicine
Aiheet:
aromatase inhibitors
breast neoplasms
Ki67 index
neoadjuvant therapy
postmenopause
tailored therapy
Linkit:https://doi.org/10.1002/cam4.1600
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia